Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Search Results

Refine Your Search

By Sector

Sort by: Date|Relevance

A New Solution for the Multibillion-Dollar Bladder Cancer Problem

Bladder cancer is the sixth-most prevalent cancer in North America and has a recurrence rate greater than 50%, making it the most expensive cancer to treat. All-in costs in the US are around $4 billion and roughly 80,000 new American cases are reported each year, with 350,000...
Stockhouse Editorial | May 25, 2020 |

FDA Grants Ampio Pharma Approval to Begin Phase 1 Trial in COVID-19 Patients

Ampio Pharmaceuticals' shares traded higher after the company reported that the FDA cleared the firm to proceed with human trials of its Investigative New Drug application for intravenous AmpionTM for treatment in COVID-19 affected patients on supplemental oxygen. ...
Streetwise Reports | June 22, 2020 |

Part III - Debt Crisis To Be Reborn In 2020

This final portion of our multiple part research post regarding the future of a crisis-like price revaluation event will focus on two components that we want to highlight for every trader, investor, and reader. It does not matter if you are invested in anything at this point –...
Chris Vermeulen | July 9, 2019 |

Mid-August Is A Critical Turning Point For US Stocks

Our cycle and predictive modeling solutions have been suggesting that Mid-August 2019 will likely prompt a major inflection point in the US stock markets and we have been attempting to warn our followers about this for months. Our continued efforts to identify this big breakdo...
Chris Vermeulen | July 15, 2019 |

Technical Analyst: As Antibiotic Resistance Rises, So May the Stock of This Livestock Feed Company

Technical analyst Clive Maund believes this stock could gain traction soon. Avivagen Inc. (VIV:TSX.V) is an interesting company because it makes farm animal feed that is free of antibiotics, which is becoming a hot topic now that over half of China's swine herd is se...
Streetwise Reports | October 16, 2019 |

Dermira's Phase 2b Atopic Dermatitis Trial Results Send Shares 25% Higher

Dermira shares traded higher today after the firm released positive data from its phase 2b study of lebrikizumab in patients with atopic dermatitis at the Las Vegas Fall Clinical Dermatology Conference. Yesterday afternoon, Dermira Inc. (DERM:NASDAQ) , a biopharmaceu...
Streetwise Reports | October 21, 2019 |

Myovant Sciences Shares Up 110% on Phase 3 Advanced Prostate Cancer Data

Shares of Myovant Sciences opened 120% higher today after the firm reported a 97% response rate in its Phase 3 HERO Study of oral Relugolix in men with advanced prostate cancer. In the study, Relugolix achieved all six key secondary endpoints and the firm expects to submit a N...
Streetwise Reports | November 20, 2019 |

Moderna Shares Rise 25% on Positive Phase 1 Coronavirus Vaccine Trial Data

Shares of Moderna Inc. traded higher, setting a new 52-week high price, after the firm reported positive interim results in its Phase 1 study of mRNA Vaccine (mRNA-1273) against SARS-CoV-2. Clinical-stage biotechnology company Moderna Inc. (MRNA:NASDAQ) , which fo...
Streetwise Reports | May 19, 2020 |

US Biopharma to Launch Phase 3 Trial in Bacterial Vaginosis

Daré Bioscience's study, its prospects and the indication's U.S. market opportunity are discussed in a ROTH Capital Partners report. In a May 15 research note, ROTH Capital Partners analyst Yasmeen Rahimi reviewed why the outlook is positive for Daré Bioscience In...
Streetwise Reports | May 21, 2020 |

Growth Is Crushing Value Right Now, but Take a Long-Term Horizon

Investors are betting on growth stocks over value stocks by a wider spread right now than at any other time since at least 1990, including during the tech bubble. The ratio between the Russell 1000 Growth Index and Russell 1000 Value Index reached a series high of 1....
Frank Holmes | May 27, 2020 |
1 2 3